Last updated on August 2020

Study to Assess the Efficacy Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma


Brief description of study

This is a phase 2, double masked, randomized, multi-center, parallel-group, 28-day study assessing the safety, tolerability and ocular hypotensive efficacy of AKB-9778 Ophthalmic Solution 4.0% administered once (AM) or twice (AM & PM) daily when used as an adjunctive therapy to latanoprost ophthalmic solution 0.005% once daily (PM) in subjects with elevated IOP due to OAG or OHT.

Clinical Study Identifier: NCT04405245

Find a site near you

Start Over

Shettle Eye Research

Largo, FL United States
  Connect »

North Valley Eye Medical Group

Mission Hills, CA United States
  Connect »

Eye Research Foundation

Newport Beach, CA United States
  Connect »

North Bay Eye Associates

Petaluma, CA United States
  Connect »

Coastal Research Associates

Roswell, GA United States
  Connect »

Kannarr Eye Care

Pittsburg, KS United States
  Connect »

Heart of America Eye Care, P.A.

Shawnee Mission, KS United States
  Connect »

Tekwani Vision Center

Saint Louis, MO United States
  Connect »

North Valley Eye Medical Group

Rochester, NY United States
  Connect »

James D. Branch, MD Ophthalmology

Winston-Salem, NC United States
  Connect »

Apex Eye

Cincinnati, OH United States
  Connect »

Abrams Eye Center

Cleveland, OH United States
  Connect »

Mark J. Weiss, MD, Inc.

Tulsa, OK United States
  Connect »

Scott & Christie and Assoc

Cranberry Township, PA United States
  Connect »

Eye Care Specialists

Kingston, PA United States
  Connect »

Total Eye Care

Memphis, TN United States
  Connect »

Advancing Vision Research

Nashville, TN United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.